Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting MSD’s oncology and potentially broader therapeutic portfolios.
